Four neutralizing monoclonal antibodies (MAbs), recognizing three functionally independent, conformational sites on type O foot-and-mouth disease virus (FMDV) failed to react with immobilized structural proteins or synthetic peptides but bound to the isolated capsid protein VP1 and peptides in solution. Inhibition ELISA techniques were, therefore, applied using peptide antigens and anti-peptide sera to block MAb binding to virus particles, permitting the identification of those portions of the VP1 protein contributing to the epitopes. The binding site of one MAb, which neutralized a range of type O FMDV isolates, was shown to have components within regions 146 to 150 and 200 to 213 of VP1 with a critical involvement of the amino acids at positions 146 and 206 or 207. The determinants recognized by two other MAbs which were directed at similar, but not identical, epitopes from a second site included components from the 200 to 213 and 143 to 146 regions with amino acids 143 and 144, respectively, appearing critical for the inhibition of the virus binding of the two antibodies. These results demonstrate that the two previously identified immunogenic tracts of VP1 are brought into proximity in the quaternary structure of the virion to form an antigenic domain containing several conformational epitopes, some of which are functionally independent. A fourth, strain-specific MAb was effectively blocked from reacting with virus by peptides corresponding to residues 161 to 180 and 200 to 213.
INTRODUCTION
In common with other picornaviruses, the capsid of foot-and-mouth disease virus (FMDV) is composed of 60 copies of each of four structural polypeptides designated VP1, VP2, VP3 and VP4. For FMDV, only VP 1, in isolation, has been shown to elicit the production of neutralizing antibodies (Laporte et al., 1973 ; Bachrach et al., 1975) . Cleavage studies of VP1 identified two immunogenic fragments composed of residues 138 to 154 and 200 to 213 (Strohmaier et al., 1982) , and synthetic peptides corresponding to these regions are capable of inducing a neutralizing antibody response (Bittle et al., 1982; Pfaff et al., 1982) .
In the accompanying paper, reciprocal cross-neutralization experiments of monoclonal antibody (MAb) escape mutant viruses were used to show that there are at least three conformational neutralizing sites on type O FMDV . However, sequence analysis of these variants showed that, surprisingly, the amino acid substitutions which conferred antibody resistance were located in regions at a distance on the linear sequence from the previously identified immunogenic tracts. Hence, although this type of study has provided useful information on the location of the major regions contributing to the native epitopes for poliovirus (Minor et al., 1983; Diamond et al., 1985) and human rhinovirus 14 (Sherry et al., 1986) it has provided little insight into the FMDV epitopes. Here we report the use of synthetic peptide antigens and their antisera to block the binding of MAbs to virus particles. This allowed 0000-8573 © 1989 SGM Polyclonal antisera. Peptide antisera were raised in either guinea-pigs or rabbits by two inoculations of 100 to 250 ~tg of peptide in isotonic saline, tn some cases the peptide was coupled to a keyhole limpet haemocyanin carrier. Antiserum to isolated VP1 polypeptide was produced by inoculating rabbits four times with 20~tg of protein eluted from PAGE gels using 0.04 M-phosphate buffer containing 0.1~ SDS. Anti-virion serum was obtained by inoculating guinea-pigs with 20 ktg of inactivated virus particles purified by the method of Brown & Cartwright (1963) . All antigens were emulsified with an equal volume of Freund's incomplete adjuvant just before injection.
ELISA techniques. Two modifications of the indirect sandwich ELISA described by Ouldridge et aL (1982) were used to map the MAb binding sites. In these assays a minimum incubation time of 1 h at 37 °C was allowed after each addition of 50 ~tl of reagent per well, apart from the first stage, followed by thorough washing with Dulbecco's phosphate-buffered saline A solution containing 0.05% Tween 20. The diluent throughout was the wash buffer supplemented with 1% bovine serum albumin. The first two stages were the same for both tests; a predetermined concentration of purified anti-virion IgG (either guinea-pig or rabbit) diluted in carbonate coating buffer (15 mMNa2CO3, 35 mM-NaHCO3) was electrostaticaUy bound to flexible PVC plates at 4 °C overnight and acted as a capture antibody for purified O IBFS virus particles at a concentration of 2 ~tg/ml.
For antibody inhibition studies, competitor antisera were serially diluted down each plate with duplicate wells for each dilution. After allowing sufficient time for binding, a constant dilution of MAb, predetermined as the dilution producing 75~ of the maximum absorbance in a standard reaction with 2 Ixg/ml of captured virus particles, was added. This was followed by the addition of peroxidase-labelled anti-MAb antibody and orthophenylenediamine/peroxide substrate in citrate buffer. Colour development was stopped with 12.5~ sulphuric acid and absorbances were read on a Titertek Multiskan spectrophotometer at 492 nm. Anti-virion and non-immune competitor sera were included in all tests as positive and negative controls respectively.
In the antigen inhibition assays, serial dilutions of competitor antigens were premixed with equal volumes of constant dilutions of the MAbs (twice the concentrations used for the antibody blocking tests) in silicone-coated vials. After allowing these to react, samples of each mixture were transferred to duplicate wells of captured 140S particles on the ELISA plates. Thereafter, conjugated anti-antibody and substrate solutions were added as above.
Non-specific background reactions were minimized in these assays by pre-absorbing the conjugates by the addition of non-immune sera (1/10) of the same species as the capture and competitor antibodies.
Polyacrylamide gel electrophoresis. Isolated viral structural polypeptides were obtained using the technique of Laemmli (1970) . Purified virus particles were dialysed against a Tris-HC1 disruption buffer containing 10~ glycerol, 1X 2-mercaptoethanol and 2~ SDS, and boiled for 5 min. The proteins were separated by electrophoresis on discontinuous polyacrylamide slab gels consisting of a 4~ stacking gel and a 12.5~ resolving gel.
RESULTS

Localization of the MAb binding sites
Initial experiments were directed at determining the viral structural protein on which the binding sites were located. The protein bands from disrupted virus separated by PAGE were transferred electrophoretically from the gels onto nitrocellulose and subjected to Western blot analysis. None of the MAbs bound, in contrast to the anti-polypeptide sera used as controls. Isolated protein bands, visualized by Coomassie Brilliant Blue staining, were eluted from gel strips with 0.04 M-phosphate buffer containing 0-19/00 SDS, diluted 1/4 in carbonate buffer and used to coat ELISA plates. At intervals of 1 h incubation at 37 °C, serial dilutions of MAbs or 
Mapping of the binding sites
Non-overlapping peptides spanning the entire length of VP1 were synthesized as 20 amino acid blocks, except the last part at the C terminus which was synthesized as a 14 residue peptide. The peptides at a concentration of 4 ~tg/ml were bound to ELISA plates and the MAbs were reacted with them as described above. No positive binding was observed for any of the MAbs with any of the immobilized peptides. In view of this and the finding that the MAbs only recognized VP 1 in free solution, subsequent studies were undertaken using competition ELISA techniques that did not require peptides to be immobilized on a solid phase.
Antibody inhibition ELISA studies
Serial doubling dilutions of antisera raised to purified virus particles, isolated VP 1, peptides derived from different regions of VP1 or peptides of varying length from the same region of VP1 were tested for their ability to block the attachment of pre-optimized concentrations of the MAbs to captured 140S virus particles. The results of the first series of duplicate or triplicate experiments are summarized in Table 1 , showing that both anti-virion and anti-VP1 sera could completely block the binding of MAbs 24.31.1, 53. 103.1 and 70.19.5, whereas antisera to the immunogenic peptides 141-160C and 200-213C each competed to a maximum level of approximately 50~ even under conditions of competitor antibody excess, as exemplified for a single MAb in Fig. 1 . A mixture of antisera to the two peptides produced inhibition curves very similar to those of VP 1 antiserum, reaching maximum inhibition values of approx. 90 ~. There was, therefore, strong evidence that both immunogenic regions of the VP 1 contributed to these three conformational epitopes.
The reason that individual peptide antisera can only inhibit 50~ of maximum colour development is not completely clear, but is most probably a reflection of the relative affinity of the MAb binding in the presence or absence of the second antibody. It is conceivable that the presence of a peptide antibody, which only physically covers part of a conformational epitope, does not actually prevent any of the MAb molecules binding, but reduces the affinity of their reactions with the virus. This appears as both a lower plateau value and a shallower slope in an ELISA titration. Thus, when the site is almost completely covered by a combination of antibodies to two peptides contributing to the determinant, true blocking occurs and the plateau and slope obtained resemble those of anti-VP1 and anti-virion sera. This hypothesis is substantiated by the finding that MAbs which react with trypsin-treated virus in solid phase ELISAs produce lower plateaux and shallower slopes with the enzymatically cleaved virus than with the intact virus , even though, by definition, the number of binding sites must remain constant.
The inhibition of MAb binding by antisera to a range of various length peptides from within the 135 to 160 region identified the binding sites more closely (Table 1) . It is clear that extending the peptide at the N terminus from amino acid 141 to amino acid 135 or reducing its length at the C terminus to amino acid 150 did not affect inhibition. This latter finding was confirmed by the total inability of peptide 150-160C antiserum to block any MAb binding. Antiserum to peptide 146-155C inhibited the binding of MAb 24.31.1 well, but had no effect on the recognition of virus by the other two antibodies. Subtractively, therefore, it is evident that region 146 to 150 is an important component of the 24.31.1 epitope, whereas region 141 to 146 is involved in binding MAbs 53. 103.1 and 70.19.5. None of the antisera to other peptides tested inhibited the reactions of MAb 24.31.1, but some inhibition (38 ~)of MAb 53.103.1 was obtained with antiserum to peptide 161-180C.
In a second series of experiments antisera to a nested set of peptides, serially decreasing in length by one amino acid at the N terminus in the range 140-160C to 148-160C, were tested for their ability to block the three MAbs. The results show sharp cutoffs of inhibition demonstrating that N 143, L 144 and G 146 are critical residues for blocking the binding of 53. 103.1, 70.19.5 and 24.31.1 respectively (Table 2) .
Antigen inhibition ELISA studies
The possibility existed that some of the reactions observed in the antibody blocking assay were the product of steric effects. Therefore, further studies were carried out using serial dilutions of peptides as competitor antigens to inhibit MAb binding to captured virus particles. Peptides 141-160C and 200-213C both successfully inhibited virus recognition by the three antibodies (Table 3) The results of the antibody competition studies also implied the involvement of one or more amino acids from the highly conserved R 145, G 146, D 147 region in the epitopes recognized by all three MAbs. Consequently a tripeptide to this RGD sequence, a heptapeptide containing this sequence flanked on either side by two FMDV type O-specific amino acids and a heptapeptide derived from Sindbis virus coat protein which also contains an RGD sequence were tested for their blocking activity against the three MAbs. The tripeptide and the FMDVspecific heptapeptide inhibited the binding of all three MAbs equally well, but the Sindbis virus heptapeptide had a variable effect ( Table 5 . Attempts were made to define the critical antibody binding region at the VP1 C terminus by synthesizing a set of equal length, overlapping peptides from this region 'frameshifted' by two amino acids from sequence 188-20lC to sequence 200-213C, and using them in antigen inhibition assays. The results of blocking experiments with 53. 103.1 and 14.7.1 antibodies were inconclusive, but the binding of MAb 24.31.1 was inhibited by peptides 194--207C to 200-213C, and not by any of the others (Table 6 ). This implies that either V 206 or A 207 is a key amino acid for the 24.31.1 binding site. The variation observed in the concentrations of peptide 200-213C required to inhibit 50~ of MAb 24.31.1 binding in the two experimental series (Tables 3 and 6 ) is most probably due to differences in the relative purities of the two batches of peptide used.
Inhibition of the virus-binding of MAb 14,7.1 by competitor peptide antigens in a sandwich ELISA
DISCUSSION
The MAbs used in this study recognize three functionally independent neutralizing sites present on O l BFS 1860/67 virus, which have all been shown to be conformational . This high degree of conformation dependence is reflected in the difficulties experienced in binding the MAbs to immobilized proteins and peptides. It probably also accounts for the finding that substitutions in the primary sequences of mutant viruses, selected under MAb pressure, occur neither in the known immunogenic tracts nor in well defined linear clusters that allowed the identification of epitopes of poliovirus (Minor et al., 1983; Diamond et al., 1985; Page et al., 1988) and human rhinovirus 14 (Sherry et al., 1986) . Nevertheless, this study shows that major components of the neutralizing sites identified are located within both known immunogenic regions. Strohmaier et al. (1982) strains, although this range is very different from 24.31.1 antibody, but reciprocal crossneutralization by these antibodies of variant viruses selected under pressure from the other MAb showed that they recognized similar, but not completely identical, epitopes .
The possibility that the two immunogenic tracts are closely juxtaposed in the tertiary structure of the VP1 molecule was originally proposed by Morrell (1983) on the basis of cross-linking studies. The first serological evidence that they both contributed to a single antigenic domain was presented in a preliminary communication of some of the data included here (Parry et al., 1985) . Subsequently, DiMarchi et al. (1986) showed that a single peptide synthesized to the sequence CC200-213-PPS-141-158-PCG was more immunogenic than peptides to each region alone, but it was considered that little or none of the increased neutralizing response was directed at the 200 to 213 region itself (Doel et al., 1988) . More recently Xie et al. (1987) have also identified neutralizing MAb binding sites on type O FMDV that contain amino acids from both regions. This report reinforces the concept that although the two regions which are independently capable of stimulating a neutralizing antibody response are linearly distant on VP1, they are in close proximity on the virion surface and form a single antigenic domain containing several epitopes of different specificities. Recent X-ray crystallographic evidence shows that these two components of a single site are provided by adjacent VP 1 molecules, the C terminus crossing the twofold protomer interface (Acharya et al., 1989) .
The mapping of those portions of the epitopes which lie within the 141 to 160 region agrees with other serological data. Geysen et al. (1984) used the reactions of rabbit anti-virion sera with overlapping hexapeptides of VP1 to identify an epitope located between amino acids 146 and 152. Francis et al. (1987) studied the immune responses to a nested set of peptides representing the 135 to 160 region of VP1 and found that the shortest peptide that was capable of inducing neutralizing antibodies, after two inoculations, was one corresponding to amino acids 146 to 160. Furthermore, peptide 144-160 evoked substantially higher levels of neutralizing antibody, while peptide 143-160 was more immunogenic still. Peptides further extended at the N terminus showed more gradual increases in immunogenicity, but this may be due to better presentation of the 141 to 150 region rather than to the incorporation of residues that are epitopic on the virus particle (Parry et al., 1988) . It has also been observed that there is greater sequence homology between amino acids 145 to 150 than between amino acids 141 to 144 for serologically related type O FMDV strains (Ouldridge et al., 1986) , which is consistent with the mapping in this region of the determinants of the broadly cross-reactive 24.31.1 antibody and the more specific 53. 103.1 and 70.19.5 antibodies.
The antigen inhibition experiments clearly indicated that the tripeptide sequence R 145, G 146, D 147, which occurs in the great majority of FMDV strains for which sequences have been published, contributes to neutralizing determinants. The specificity of the antibody recognition of these determinants is dependent, however, on the flanking sequences. Thus, a tripeptide or heptapeptide specific for the FMDV sequence inhibited the three MAbs equally, whereas the RGD-containing heptapeptide derived from Sindbis virus coat protein effectively blocked MAb 70.19.5 which mapped most centrally over the RGD region, but was less effective in blocking the two MAbs whose epitopes include a greater number of flanking amino acids. Conceivably, this regulatory effect would also be provided by non-contiguous regions of VP1 or the other structural proteins brought into proximity by the quaternary structure of the capsid. This form of control presumably also minimizes the polyclonal antibody cross-reactivity between virus serotypes, although antisera to some peptides containing the RGD region of type O FMDV can cross-neutralizesome type A and C viruses (N. R. Parry & F. Brown, unpublished data) . The conservation of the RGD tract is not due, therefore, to inaccessibility to antibodies allowing it to escape immune pressure, but probably because it is required for an indispensable biological function such as attachment to cells (Geysen et al., 1985; Fox et al., 1989) .
The epitope recognized by MAb 14.7.1 appeared to consist of components derived from two regions of VP 1 separated on the linear sequence. In common with the three other epitopes, one of the components is located within the 200 to 213 region. The second portion of this site has been identified between residue 161 and residue 180. Robertson et al. (1984) have previously reported that amino acids 169 to 179 contribute to a neutralizing epitope of type A FMDV, and a peptide corresponding to the type O 161 to 180 amino acid sequence is able to induce low levels of neutralizing antibody in rabbits (mean serum titre in mouse index test is 1/160 compared to < 1/10 for preimmune sera: F. Brown, unpublished data).
Both preliminary crystallographic data and molecular models suggest that the ability of antipeptide 161-180C serum to inhibit the binding of MAb 53.103.1 was not due to partial blocking of the epitope itself. This agrees with the finding that it was not possible to inhibit the virus recognition of this MAb with the peptide antigen. It may be that the pre-reaction with peptide 161-180C antibodies induced sufficient distortion of the virus capsid to prevent subsequent attachment of MAb 53. 103.1.
One of the components identified for the 14.7.1 epitope occurs in a region of VP1 that is unaffected when the intact virus is treated with trypsin, which accounts for the continued reaction of this antibody with enzyme-treated virus. The mapped components of the binding sites of the other MAbs, however, are all located within trypsin-sensitive tracts of VP1 (Strohmaier et al., 1982) , yet these antibodies continue to recognize cleaved virus in solution assays although their reactivity in solid phase assays is altered . One possible explanation for this is that the enzyme cleavage fragments remain in association with the virus particle until it is disrupted for electrophoresis, but the lack of reactivity of trypsin-treated virus in ELISA and radioimmune precipitation titrations with the appropriate peptide antisera show that this is probably not the case (N. R. Parry & G. Fox, unpublished data) . A second, more likely, possibility is that these epitopes contain a third component which has yet to be identified. For the related 53. 103.1 and 70.19.5 determinants the probable location of a third moiety is in VP2, as seven out of nine variant viruses selected under pressure from these two antibodies possess VP2 proteins with a substitution at position 134 , which is exposed on the virus surface approximately 100 nm from the major VP1 loop.
The evidence for the possible location of a third component of the 24.31.1 binding site is somewhat ambiguous. Although some MAb 24.31.1-resistant variant viruses have amino acid substitutions at VP 1 positions 43 and 48, neither peptide 41-60C nor its antiserum were able to block the binding of this antibody. Analysis of crystallographic X-ray diffraction data suggests, however, that amino acids 41 to 50 could form a surface loop close to the 141 to 160 region (Acharya et al., 1989) , but as the exact position of the latter has yet to be determined it is possible that it could mask the 41 to 50 tract. The finding that peptide 41-60C antisera do not recognize intact virus particles in a sandwich ELISA or precipitate them in a radioimmune assay, but do bind both to captured trypsin-treated particles, from which VP1 amino acids 138 to 154 have been excised (Strohmaier et al., 1982) , and to intact virus particles in an indirect ELISA, in which virions are distorted (McCullough et al., 1985) , suggest that these antibodies can recognize the native 41 to 60 region, but that it is normally inaccessible on the intact virus (N. R. Parry, unpublished data). Thus, the 41 to 50 loop may either have insufficient amino acids exposed on the virus surface for recognition by antipeptide antibodies, but those that are exposed interact with the immunogenic regions to form the binding site of MAb 24.31.1 or, alternatively, its proximity to the epitope may indirectly affect the conformation. There is some serological data to support the second hypothesis in that the ability of antisera to both peptide 141-160C and peptide 200-213C to neutralize and to bind the 24.31.1-resistant variants was reduced in comparison with the parental virus (data not shown). Since the variant viruses show complete homology with the parental virus in the sequences represented by these peptides, their altered reactivity with the antisera suggests that the substitutions at residue 43 can affect the antigenic characteristics of the 141 to 160 and 200 to 213 regions. Although the majority of amino acid substitutions conferring viral resistance to antibody are located within the binding sites, the occurrence of mutations outside the sites have been described for tobacco mosaic virus (A1 Moudallal et al., 1982) and feline leukaemia virus (Nicolaisen-Strauss et al., 1987) . The suggestion that it also occurred for poliovirus 1 (Diamond et al., 1985) was not substantiated when the atomic structure of the virus was resolved by Hogle et al. (1985) . This latter group, however, do not preclude that it may be the basis of a substitution at position 270 of VP2 allowing poliovirus 1 to escape neutralization by a MAb whose binding site is composed of VP1 residues 221 to 226 and VP2 residues 164 to 170 (Page et al., 1988) . It is, therefore, conceivable that linearly distant mutations which occur spatially close to a conformational epitope of FMDV could alter the relative orientation of the components and so prevent its recognition by a MAb. Resolution of the molecular architecture of the parental virus and a MAb-selected variant may help to solve this interesting problem. To this end the viruses have been crystallized (Fox et al., 1987) , and analysis of X-ray diffraction data is nearing completion (D. Stuart, personal communication) .
Since the submission of our manuscripts Thomas et al. (1988; Journal of Virology 62, 2782 -2789 have described the mapping of MAbs to an Alo strain of FMDV. The majority of these bind to immobilized peptides, emphasising the more conformation-dependent nature of epitopes on type O viruses. Some of their epitopesare discontinuous, in particular one shows some structural similarity to our 53. 103.1 and 70.19.5 epitopes in that it contains VP2 residue 132 and VP1 residue 146. They also indicate that VP1 residue 169 contributes to an independent site which may be equivalent to our 14.7.1 site.
